Last reviewed · How we verify
AGN-151607
AGN-151607 is a small molecule that targets the S1P1 receptor.
AGN-151607 is a small molecule that targets the S1P1 receptor. Used for Relapsing forms of multiple sclerosis.
At a glance
| Generic name | AGN-151607 |
|---|---|
| Sponsor | AbbVie |
| Drug class | S1P1 receptor modulator |
| Target | S1P1 |
| Modality | Small molecule |
| Therapeutic area | Autoimmune diseases |
| Phase | Phase 2 |
Mechanism of action
AGN-151607 works by binding to the sphingosine-1-phosphate 1 (S1P1) receptor, which is involved in the regulation of lymphocyte trafficking and immune responses. This mechanism of action is thought to contribute to its therapeutic effects in treating autoimmune diseases.
Approved indications
- Relapsing forms of multiple sclerosis
Common side effects
- Headache
- Nausea
- Diarrhea
- Fatigue
Key clinical trials
- Study of AGN-151607-DP to Assess Adverse Events and Change in Disease Activity in Adult Participants Undergoing Open Abdominal Ventral Hernia Repair (PHASE2)
- Botulinum Toxin Type A (AGN-151607) for the Prevention of Post-operative Atrial Fibrillation in Adult Participants Undergoing Open-chest Cardiac Surgery (NOVA) (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- AGN-151607 CI brief — competitive landscape report
- AGN-151607 updates RSS · CI watch RSS
- AbbVie portfolio CI